Clinical experience in open-label studies and anectodal reports suggest that levetiracetam is effective in generalized epilepsy. In this open-label prospective study, 19 patients (3 men, 16 women) affected by idiopathic generalized epilepsy were followed for at least 6 months following the introduction of levetiracetam. Patients were categorized according to syndrome subtype: juvenile myoclonic epilepsy (8), juvenile absence epilepsy (5), childhood absence epilepsy (4), and eyelid myoclonia with absences (2). Eleven patients received levetiracetam as monotherapy, eight as add-on therapy. Effectiveness was demonstrated in 18 patients: 13 became seizure-free (five juvenile myoclonic epilepsy, five juvenile absence epilepsy, three childhood absence epilepsy), and five achieved significant reductions in seizure frequency (three juvenile myoclonic epilepsy, one childhood absence epilepsy, one eyelid myoclonia with absences). Only one patient experienced no change in seizure frequency (eyelid myoclonia with absences). Clinical improvement was accompanied by EEG abnormality suppression or reduction. Levetiracetam was well tolerated; no patient reported side-effects.

Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes / Di Bonaventura, Carlo; Fattouch, Jinane; Mari, Francesco; Egeo, Gabriella; Vaudano, Anna Elisabetta; Prencipe, Massimiliano; Manfredi, Mario; Giallonardo, Anna Teresa. - In: EPILEPTIC DISORDERS. - ISSN 1294-9361. - 7:3(2005), pp. 231-235.

Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes

VAUDANO, Anna Elisabetta;
2005

Abstract

Clinical experience in open-label studies and anectodal reports suggest that levetiracetam is effective in generalized epilepsy. In this open-label prospective study, 19 patients (3 men, 16 women) affected by idiopathic generalized epilepsy were followed for at least 6 months following the introduction of levetiracetam. Patients were categorized according to syndrome subtype: juvenile myoclonic epilepsy (8), juvenile absence epilepsy (5), childhood absence epilepsy (4), and eyelid myoclonia with absences (2). Eleven patients received levetiracetam as monotherapy, eight as add-on therapy. Effectiveness was demonstrated in 18 patients: 13 became seizure-free (five juvenile myoclonic epilepsy, five juvenile absence epilepsy, three childhood absence epilepsy), and five achieved significant reductions in seizure frequency (three juvenile myoclonic epilepsy, one childhood absence epilepsy, one eyelid myoclonia with absences). Only one patient experienced no change in seizure frequency (eyelid myoclonia with absences). Clinical improvement was accompanied by EEG abnormality suppression or reduction. Levetiracetam was well tolerated; no patient reported side-effects.
7
3
231
235
Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes / Di Bonaventura, Carlo; Fattouch, Jinane; Mari, Francesco; Egeo, Gabriella; Vaudano, Anna Elisabetta; Prencipe, Massimiliano; Manfredi, Mario; Giallonardo, Anna Teresa. - In: EPILEPTIC DISORDERS. - ISSN 1294-9361. - 7:3(2005), pp. 231-235.
Di Bonaventura, Carlo; Fattouch, Jinane; Mari, Francesco; Egeo, Gabriella; Vaudano, Anna Elisabetta; Prencipe, Massimiliano; Manfredi, Mario; Giallonardo, Anna Teresa
File in questo prodotto:
File Dimensione Formato  
DIBONAVENTURA_EPILEPTICDISORD-2005.pdf

non disponibili

Dimensione 43.97 kB
Formato Adobe PDF
43.97 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1268269
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 31
social impact